olaparib
Showing 376 - 385 of 385
OSCA - Olaparib Standard of CAre Study
Completed
- Platinum-sensitive Recurrent Serous Ovarian Cancer
- Data Collection
-
Ballarat, Australia
- +198 more
Feb 28, 2017
Pancreatic Tumors Trial in United Kingdom, United States (KU-0059436 (AZD2281)(PARP inhibitor), Gemcitabine)
Completed
- Pancreatic Neoplasms
- KU-0059436 (AZD2281)(PARP inhibitor)
- Gemcitabine
-
New York, New York
- +3 more
Dec 19, 2013
Carcinoma of the Oesophagus Trial in Manchester, Southampton (Olaparib, Radical external beam radiotherapy, 50Gy in 25
Unknown status
- Carcinoma of the Oesophagus
- Olaparib
- Radical external beam radiotherapy, 50Gy in 25 fractions
-
Manchester, United Kingdom
- +1 more
Aug 16, 2013
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Boston (Olaparib)
Withdrawn
- Ovarian Cancer
- +2 more
- Olaparib
-
Boston, MassachusettsDana-Farber Cancer Institute
Aug 18, 2012
Carcinoma, Squamous Cell Trial (olaparib, cisplatin, Intensity Modulated Radiotherapy)
Withdrawn
- Carcinoma, Squamous Cell
- olaparib
- +2 more
- (no location specified)
May 29, 2012
Malignant Solid Tumors Trial in Glasgow, Leicester, Manchester (KU-0059436 (AZD2281)(PARP inhibitor), Topotecan)
Completed
- Malignant Solid Tumors
- KU-0059436 (AZD2281)(PARP inhibitor)
- Topotecan
-
Glasgow, United Kingdom
- +2 more
Dec 7, 2010
Advanced Solid Malignancies Trial in Tokyo (KU-0059436 (AZD2281)(PARP inhibitor))
Completed
- Advanced Solid Malignancies
- KU-0059436 (AZD2281)(PARP inhibitor)
-
Tokyo, JapanResearch Site
Aug 19, 2009
Melanoma Tumors Trial in United Kingdom, United States (KU-0059436 (AZD2281)(PARP inhibitor), dacarbazine)
Completed
- Melanoma Neoplasms
- KU-0059436 (AZD2281)(PARP inhibitor)
- dacarbazine
-
Pittsburgh, Pennsylvania
- +3 more
May 14, 2009